These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8004701)

  • 21. Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Itoh K; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):541-50. PubMed ID: 8004699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives.
    Navarrete-Vázquez G; Hidalgo-Figueroa S; Torres-Piedra M; Vergara-Galicia J; Rivera-Leyva JC; Estrada-Soto S; León-Rivera I; Aguilar-Guardarrama B; Rios-Gómez Y; Villalobos-Molina R; Ibarra-Barajas M
    Bioorg Med Chem; 2010 Jun; 18(11):3985-91. PubMed ID: 20451399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and antiplatelet activity of new imidazole-4-carboxylic acid derivatives.
    Rehse K; Steege J
    Arch Pharm (Weinheim); 2005 Nov; 338(11):539-47. PubMed ID: 16281307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, antiplatelet and vasorelaxing activities of xanthone derivatives.
    Lin KW; Fang SC; Hung CF; Shieh BJ; Yang SC; Teng CM; Lin CN
    Arch Pharm (Weinheim); 2009 Jan; 342(1):19-26. PubMed ID: 19035386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):551-9. PubMed ID: 8004700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
    Dickinson RP; Dack KN; Long CJ; Steele J
    J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclic guanidines. 17. Novel (N-substituted amino)imidazo[2,1-b]quinazolin-2 ones: water-soluble platelet aggregation inhibitors.
    Ishikawa F; Saegusa J; Inamura K; Sakuma K; Ashida S
    J Med Chem; 1985 Oct; 28(10):1387-93. PubMed ID: 4045917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyridazines. XIII. Synthesis of 6-aryl-5-oxygenated substituted-3(2H)-pyridazinones and evaluation as platelet aggregation inhibitors.
    Laguna R; Rodriguez-Liñares B; Cano E; Estevez I; Raviña E; Sotelo E
    Chem Pharm Bull (Tokyo); 1997 Jul; 45(7):1151-5. PubMed ID: 9246748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition.
    Chłopicki S; Koda M; Chabielska E; Buczko W; Gryglewski RJ
    J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):715-22. PubMed ID: 11192944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines.
    Ihmaid SK; Al-Rawi JM; Bradley CJ; Angove MJ; Robertson MN
    Eur J Med Chem; 2012 Nov; 57():85-101. PubMed ID: 23059543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
    J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclic guanidines. 14. Imidazo[1,2-a]thienopyrimidin-2-one derivatives as blood platelet aggregation inhibitors.
    Ishikawa F; Kosasayama A; Yamaguchi H; Watanabe Y; Saegusa J; Shibamura S; Sakuma K; Ashida S; Abiko Y
    J Med Chem; 1981 Apr; 24(4):376-82. PubMed ID: 7265124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) on rabbit platelet aggregation in vitro and rat platelet retention.
    Umetsu T; Kato T
    Thromb Haemost; 1978 Feb; 39(1):167-76. PubMed ID: 580491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New pyridazino[4,5-b]indole derivatives with inodilator and antiaggregatory activities.
    Monge A; Aldana I; Losa MJ; Font M; Cenarruzabeitia E; Castiella E; Frechilla D; Santiago E; Martínez de Irujo JJ; Alberdi E
    Arzneimittelforschung; 1993 Nov; 43(11):1175-80. PubMed ID: 8292060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities.
    Amin EN; Abdel-Alim AA; Abdel-Moty SG; El-Shorbagi AN; Abdel-Rahman MSh
    Arch Pharm Res; 2010 Jan; 33(1):25-46. PubMed ID: 20191341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T; Morishima Y; Watanabe K; Takahashi M; Shibano T
    Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Synthesis and platelet aggregation inhibitory activity of 6-substituted dihydropyridazinones].
    Yao FM; Sun CS
    Yao Xue Xue Bao; 1993; 28(7):548-52. PubMed ID: 8285059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.